Exagen, Inc., is a commercial stage company focused on developing and marketing products to community rheumatologists. Exagen’s flagship diagnostic product, AVISE CTD, is a proprietary test to assist in the diagnosis of systemic lupus erythematosus (SLE or lupus) based on the Company’s proprietary Cell-Bound Complement Activation Products (CB-CAPs) technology. In addition to AVISE CTD, Exagen provides physicians with a panel of biomarkers for the diagnosis of other connective tissue diseases (e.g., rheumatoid arthritis and scleroderma), based on its CB-CAPs technology. Exagen is also focused on leveraging its commercial organization to market Simponi, a TNF inhibitor developed by JNJ, approved for the treatment of several autoimmune conditions, including rheumatoid arthritis.
For more information visit: https://www.exagen.com/